Amendment to the Claims

The claims before the Examiner are new claims 8-15. Support for these claims can be found in the specification and working examples.

Originally filed claims 1-5 are hereby cancelled. Claims 6 and 7 were cancelled by Applicant via a restriction requirement imposed by the Examiner. New claims 8-15 are listed below.

Listing of Claims

1. Cancelled by this Response.

2. Cancelled by this Response.

3. Cancelled by this Response.

4. Cancelled by this Response.

5. Cancelled by this Response.

6. Cancelled by Applicant as a result of a restriction requirement.

7. Cancelled by Applicant as a result of a restriction requirement.

8. (new) A method of inhibiting the attachment of *Haemophilus influenzae* to human cells by administering to a human from 0.01 to 20 grams of a composition comprising at least one component selected from peaks 1, 6 and 7 of a C18-HPLC of an aqueous extract of at least one plant selected from the group consisting of *Pogostemon cablin* and *Agastache rugosa*, said C18-HPLC being conducted under the conditions as follows:

a) column: Rainin Microsorb-MV™ C18 column (5-μm particle size, 100Å pore size, 4.6 mm ID x 25 cm L);

b) mobile phase: EtOH/0.2 N NH_4HCO_3 (2/98, v/v) where the EtOH stands for a reagent alcohol consisting of 90.5% ethanol, 4.5% methanol and 5.0% isopropanol;

c) flow rate: 0.80 ml/min;

d) d tector: UV detector at 214 nm and 0.030 AUFS; and
) run time: 40 minut s

9. (new) The method of claim 8 wherein said component is characterized by peaks 1, 6 and 7 in Figures 1A, 1B, 3A and 3B.

10. (new) The method of claim 8 wherein said human is an infant.

11. (new) The method according to claim 8 wherein at least 0.4 grams of the composition is administered per day.

12. (new) The method according to claim 8 wherein said composition further comprises an additive, selected from the group consisting of candies, confections, gels, nutritional supplements, chewing gums, medical and infant nutritionals, beverages, yogurts, milk, rehydration solutions and aqueous solutions.

13. (new) The method according to claim 8 wherein said composition is administered through the oral route.

14. (new) The method according to claim 8 wherein said composition is administered through the nasal route.

15. (new) The method according to claim 8 wherein said composition is in the form of a tablet, lozenge, jelly, or chewing gum that dissolves in the mouth to bathe the nasopharynx of said human.